Viewing Study NCT04300803

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:49 PM
Ignite Modification Date: 2026-03-06 @ 11:07 AM
Study NCT ID: NCT04300803
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2020-08-28
First Post: 2020-03-05
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
Sponsor: MorphoSys AG
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None DLBCL View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Tafasitamab View
None MOR00208 View
None MOR208 View
None monoclonal anti-CD19 antibody View
None Diffuse large B-cell lymphoma View